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Abstract 
The novel recombinant eukaryotic VRPIL4/6 p lasmid, the secretory VR1020 vector containing fused pig IL-6 
and IL-4 genes, was encapsulated with chitosan nanoparticles  (CNP) prepared by use of ionotropic gelat ion 
method and then used to inoculate intramuscularly forty 14-day-old piglets using 0.5, 1.0 or 1.5 mg/per animal, 
which were simultaneously injected with inactivated Mycoplasmahyopneumoniae vaccine and challenged on 10 
weeks post vaccination, which were designated as group A1, A2 and A3. Blood was collected every two weeks 
from the piglets after vaccination to detect the changes in immunoglobulin, specific antibod y, IL-2, IL-4 IL-6, 
IFN- immune cells. Compared to the control piglets with VR1020-CNP, the concentration of IgG, IgA and 
IgM, specific antibody, interleukins and IFN- of the groups treated with the 
fusion genes from 14 to 70 days after vaccination (P<0.05);  furthermore, the number of TH, TC and CD3+  T cells 
was raised significantly in the blood of the treated piglets (P<0.05). Meanwhile, the lymphocytes and monocytes 
also significantly rose in the treated groups (P<0.05). The humoral and cellu lar immune indexes of the A3 group 
increased to different extents in  comparison with those of A1 and A2 group from 14 to  56 days post inoculation  
(P>0.05 or P<0.05). The protection against challenge with viru lent M hyo and growth performance of the treated 
pigs is markedly better than those of the control animal (P<0.05). These results indicated that VRPIL4/6 
entrapped with CNP can enhance the humoral and cellu lar immunity of pigs to Mycoplasmahyopneumoniae
vaccine, and elevate the immunoprotection level of treated animal, which could facilitate the development of 
effective immunoadjuvant against Mycoplasmahyopneumoniae of pig. 
© 2012 Published by Elsevier Ltd. Select ion and/or peer-review under responsibility of ISV  
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1. Introduction 
Presently, adjuvant for conventional vaccines is very critical for successful prevention and control of animal 
infectious diseases. Antigenicity of conventional vaccines can be modulated by ad juvant  to promote the 
production of antibody and cellu lar immune responses for better immunoprotection. Cytokines had been 
employed as novel and effective adjuvant to regulate the immunity of animals due to their safety and 
effectiveness, including interleukins, interferon and granulocyte macrophage colony stimulat ing factors  (GM -
CSF) [1, 2]. Moreover, fusion cytokines, such as GM-CSF/IL-3, G-CSF/GM-CSF and GMCSF/IL-6, were 
reported to display stronger bioactivities than the original cytokines  [3,4,5]. But until now, the cytokine proteins  
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are not put into practical use to boost immunity of animals against infectious diseases due to cost and short 
bioactivity in vivo.  Recently, some cytokine genes were utilized to develop safer and better adjuvant to 
improve the immunity and resistance of animals against infectious diseases[6,7,17], and they could overcome 
possible side effects caused the excessive use of cytokine proteins, suggesting  a new way to develop safe and 
effective adjuvant for animal vaccine.   
Mycoplasma hypopneumoniaee (M hyo) is a widespread chronic respiratory porcine disease characterized 
clin ically by  a dry  sporadic, and non-productive cough [9]. This d isease inflicts important economic losses to 
swine industry worldwide due to the reduced performance of p ig growth and increased susceptibility of p igs to 
other infectious diseases [10].  
Unfortunately, current  M hyo vaccines usually provide partial protection of p igs against re-infect ions and lung 
lesions [10, 13], and could not provoke immunity enough to eliminate M. hyopneumoniae from infected pigs [12, 
14]. Nowadays, there still lacks effective ad juvant for M hyo vaccination.  Therefore, fo r the sake of exploring a 
safe and practicable adjuvant to boost pig immunity to vaccine and improve the control of M hyo, the present 
study was firstly conducted to employ fused gene for pig IL-4 and IL-6 packaged in chitosan nanoparticle (CNP) 
to amplify the immunity of pig lets to M hyo vaccine.   
2. Materials and methods  
2.1 Conventional vaccine  
The inactivated Mycoplasma hyopneumoniae (M hyo) vaccine (produced by Chengdu Medicine and 
Appliances Factory, China) was used in this experiment as  a conventional vaccine to immunize  Landrace-
Yorkshire-Chuanbai hybrid swine. One dose for pig vaccination includes 2 108 CFU/ml of inactivated 
Mycoplasma pneumonia. 
2.2 Fusion gene of porcine IL-6 and IL-4  
VRPIL4/6 expression plasmids and the eukaryotic secretory VR1020 p lasmids (provided by Vical company, 
San Diego, CA, USA) containing fused porcine IL-6 and IL-4 gene were prepared in our lab [35] and the 
VRPIL4/6 expression plasmids and the eukaryotic secretory VR1020 p lasmids (provided by Vical company, 
San Diego, CA, USA) containing fused porcine IL-6 and IL-4 gene were prepared in our lab [6]  
2.3  Large-scale preparation of the recombinant plas mids  
A single colony of E. coli containing the recombinant VRPIL4/6 plas mids was used to inoculate 400 ml 
Lurea Bertani (LB) b roth containing kanamycin at 100 g/ml and shaken for 16 h at 37 C. The recombinant 
plasmids were extracted following large-scale alkaline lysis., precipitated and purified by the spermine method 
[15]. Then, the plasmids were suspended in sterile saline water and stored at 20 C until use. 
2.4  Preparation and detection of VRPIL4/6 encapsulated in chitosan nanoparticle (CNP) 
Chitosan was provided by the Chengdu Organic Chemistry Institute of China, Academy of Science. Its 
molecular weight is 150 kDa  and the deacetyl degree is over 95%.CNP entrapped VRPIL4/6 (VRPIL4/6-CNP) 
was prepared using the ionotropic gelation method[7].  
2.5 Detection of endotoxin in VPIL4/ 6-CNP 
The possible residual contamination by endogenous toxin from E. coli in VPIL4/6-CNP was detected using 
the standard coagulation of Limulus Amebocyte lysate test [17] and the content of endogenous toxin in the 
packed plasmids was shown to be less than 0.1 EU/mg.  
2.6 VPIL4/6-CNP gel retardation assay 
The packing rate of VRPIL4/6 with CNP was observed using 1.0% agarose gel electrophoresis with ethidium 
bromide. 
2.7 Animal vaccination and challenge 
Forty 14-day healthy piglets, Landrace-Yorkshire-Chuanbai crossbred, weighing 3-4 kg, were randomly  
divided into the groups A1, A2, A3 and C, 10 pig lets per group. Group A1, A2 and A3 were designated as the 
treated groups to inject intramuscularly with 0.5 mg, 1.0mg or 1.5mg of VRPIL4/6-CNP respectively via syringe 
with No.12 needle in neck, while pigs in  group C were each injected with 1.5 mg of VR1020-CNP. 
Simultaneously these four groups of piglets were intramuscularly injected via syringe with No.12 needle with the 
same amount of M hyo vaccine (4 ml, 5×107 CFU/ ml inactivated M.hyo per piglet). 5 ml blood samples were 
collected from the pigs on days 0, 14, 28, 42, 56 and 70 after vaccination to assay the immunological changes. 
All the pigs were bred under the same condition, and the init ial and final weights of experimental p igs in each 
group were respectively recorded to compare the effect of inoculation on animal growth performance.  
10 weeks post vaccination, all the experimental p igs were intratracheally inoculated with 2mL derivative of 
M.hyo MY-90 (109 CCU per mL, prov ided by Center of Animal Disease Control of Sichuan Province), and were 
euthanized using intravenous admin istration of sodium pentobarbital on 28 days post challenge. The lungs were 
collected from the pigs to evaluate the lesions consistent with  M hyopneumonia as prev ious report [18]. 
Bronchial alveolar lavage fluids (BALF) were co llected by use of 15ml o f sterile phosphate buffered saline (PBS)  
to wash the bronchus and alveoli after lesion examination, and BALF samples were assayed for M hyo DNA by 
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PCR. For PCR detection of specific M hyo pathogen, a 1 mL aliquot of BALF from each pig was centrifuged.
The resulting pellet was resuspended in 200 L of PBS and M hyo DNA was isolated using the QIAamp DNA
mini kit  (Qiagen, Valencia, Californ ia). The primers for M hyo were designed as following: forward, 5 -
CCGATTAGTGTCCCGTTATG-3 , reverse, 5 -AGATGAATCACCATGTTC ACCCAT-3 , which targets to 
amplify 300bp specific DNA fragment of M hyo[19]. Nose swabs were also collected from the pigs on 14, 28,
42, 56 and 70 days post vaccination to detect M hyo DNA by the same way.
The investigators were blinded to the vaccination status of the pigs until all experimental results were
collected. The care and use of experimental pig lets rationally complied with Chinese animal welfare laws,
guidelines and regulations. 
2.8 Immunological assays
2.8.1 Assay of s pecific antibody-SABC ELIS A
An endpoint ELISA was performed to assess the titers of anti-Mycoplasma antibody in the sera of pig lets
using Mycoplasma antigenic proteins (from Chengdu Medicine and Appliances Factory, China). In short, 96-
well flat-bottom p lates (Nuclon, Roskilde, Denmark) were coated with the antigenic proteins (5 g/ml) 
overnight at 4 C, and then the following steps were as the previous report [8].
2.8.2 Assay of IgG, IgM and IgA-Sandwich ELIS A
Pig IgG, IgM and IgA quantization ELISA kits were purchased from Bethyl Laboratory (Inc., America) to
detect the changes in immunoglobulins in the sera of experimental pig lets as the  report [8].
2.8. 3 Assay of IL-2, IL-4, IL- 6 and IFN- - S andwich ELISA
To evaluate the effects of recombinant plasmids on cytokine production of pig, ELISA Kits (R&D Systems,
Inc. 614 McKin ley Place NE Minneapolis, MN 55413) were used to evaluate the cytokine in piglet serum as
the previous description [8].
2.8.4 Assay of immune cells quantity in the peripheral blood
The immune cells of p iglets were counted using a routine method, the automatic counting of blood cells with
Excell/TM 22 automatic blood cell counter (Denam Company, USA).
2.8.5 Assay of T subpopulation cells 
Two-color FCM analysis: Mouse mAbs against porcine CD3, CD4 and CD8, labeled with fluorescein
isothiocyanate (FITC) and R-phycoerythrin (R-PE) respectively, were purchased from SouthernBiotech 
(Birmingham, USA). A d irect immunofluorescence staining of whole b lood was as previous report [8].
2.9 Statistical analysis
Data was evaluated t-test of variance analysis. Differences between group means from 
experimental pig lets were considered statistically significant when P<0.05.
3. Results
3.1 Humoral immune res ponse to vaccine
Figure 1 shows the changes of Mycoplasma antibody and immunoglobulins in the sera from the vaccinated
piglets. By 14 days after vaccination, specific antibody against Mycoplasma antigens could be detected and the
amount of Mycoplasma antibody in the treated piglets (A1, A2 and A3 group) was significantly h igher than the 
control piglets (group C) from 14 to 70 days post immunizat ion (PI) (P<0.05). The antibody in group A3 rose 
substantially from 28 to 42 days after vaccination compared with that of A1 and A2 group (P<0.05), but the 
difference between A1 and A2 group was not significant (P>0.05).
Meanwhile, IgG, IgM and IgA were significantly elevated in  the sera of the t reated piglets compared  with
those of the control group from 14 to 70 days after vaccination (P<0.05) and the levels of IgG and IgA in A3
group were also significantly higher than those of A1 or A2 group from 14 to 70 or 28 to 56 days PI (P<0.05).
Noticeably, the content of immunoglobulins in the treated groups was enhanced with the increase of VRPIL4/6-
CNP (P<0.05), p redominantly IgG. These results clearly proved that VRPIL4/6-CNP can enhance the 
immunoglobulin production and improve the humoral immunity of the piglets to M hyo vaccine.
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Figure 1. Changes of anti-Mycoplasma antibody and immunoglobulins in  the sera from piglets . a: The level of 
anti-Mycoplasma antibody in the treated piglets (A1, A2 and A3 groups) significantly increased in comparison 
with that of the control pig lets (group C) from 14 to 70 days post immunizat ion (PI) (P<0.05). b: IgG 
significantly increased in the sera of the treated piglets in comparison with that of the control pig lets from 14 to
70 days PI (P<0.05). c: IgA amount in the sera is significantly different between the treated and the control 
piglets from 14 to 70 days PI (P<0.05), and IgA increased significantly in the A3 group compared with the A1
or A2 group. d: With the increase of VRPIL4/6-CNP, the levels of IgM in  the treated groups were significantly
higher than that of the control group from 14 to 70 days PI (P<0.05).
3.2. Cytokines in the sera of experimental piglets
The results shown in Figure 2 indicate that compared with the control piglets, the level of IL-2, IL-4, IL-6
and INF- in the sera of the treated piglets from 14 to 70 days PI (P<0.05). The 
concentrations of IL-2, IL-6 and IL-4 in A3 group were clearly higher than those of A1 and A2 group from 14 
to 56 or 70 days PI (P<0.05), while the difference between  A1 and A2 group was not significant (P>0.05). The 
level of INF- in A3 group obviously increased in comparison with A1 and A2 group from 42 to 56 days PI
(P<0.05), but the difference between A1 and A2 group was again not significant (P>0.05).
a                                                                                                 b
c                                                                                              d
Figure 2. Change of the cytokines in the sera of experimental pig lets. a:The level of IL-2 in the sera of the treated
piglets increased significantly from 14 to 70 days PI (P<0.05). b The amount of IL-4 in the sera of treated piglets
significantly raised in comparison with that of the control from 14 to 70 days PI (P<0.05), so did the IL-4 in the
A3 group compared with that of the A1 group (P<0.05). c: The content of IL-6 in the sera of the treated piglets
was significantly higher than that of the control from 14 to 70 days PI (P<0.05). d: The level of INF-
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treated piglets was significantly higher than that of the control piglets (group C) from 14 to 70 days after 
vaccination (P < 0.05)
3.3. Change of immune cells
It was observed that the numbers of lymphocytes and monocytes in the treated groups significantly increased 
in comparison with the control group from 14 to 70 days PI (P<0.05) (Figure 3a, 3c). However, the
granulocytes did not show any evident difference among the treated groups and control group from 14 to 70
days after vaccination (P>0.05) (Figure 3b). Among the treated groups, the differences in the number of 
lymphocytes and monocytes in the blood were also not remarkable (P>0.05).
a                                                                                    b
Figure 3. Change of immune cells in the b lood of the
experimental p iglets. a:The lymphocytes significantly
increased in the treated groups compared with the control 
group from 14 to 70 days PI (P<0.05), but there was no 
significant differences among the three treated groups
(P>0.05). b:The number of granulocytes was not 
significantly different among the treated groups and the
control group during the all experimental period (P>0.05).
c:The number of monocytes in the treated groups was
significantly higher than that of the control group from 14 
to 70 days PI (P<0.05)
c
3.4. T cells in the peripheral blood
Figure 4 shows that after vaccination, the numbers of CD3+, CD4+ and CD8+ T cells significantly increased
in the peripheral b lood of the treated groups compared with the control group from 14 to 70 days PI (P<0.05)
and the number of TH and TC of A3 group were clearly higher than those of A1 group from 14 to 70 days PI
(P<0.05), while the differences of these T cells were not obvious between A1 and A2 groups or between A3 
and A2 groups (P>0.05).
  b
a                                         
Figure 4. Change of T cells in  the peripheral blood of 
the experimental pig lets. a: The number of CD3 T
cells in the treated groups was significantly higher than
that of the control group from 14 to 70 days PI
(P<0.05). b: The amount of CD4 TH significantly
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increased in treated groups in comparison with that of the control group from 14 to 70 days PI (P<0.05), and so 
did the amount of CD4  TH in A3 group compared with A1 group (P<0.05). c: Compared with the control group, 
the number of CD8  TC in treated groups significantly rose from 14 to 70 days PI (P<0.05), and so did that of A3 
group than A1 groups from 42 to 70 days PI (P<0.05).  
3.5. Growth performance of vaccinated pigs  
The observation on growth performance of the p igs was recorded during the whole experiment period. The 
results indicated that the weight gain of pigs with VRPIL4/6-CNP was evidently  higher than that of the controls 
(P<0.05, Table 1), and there is no obvious differences among the three treated groups (P>0.05).  
Table 1 Effect of vaccination on the weight gain of experimental piglets (n=10)  
Group Initial weight (kg) End weight (kg) Net gain (kg) Average gain (kg) 
A1 3.3±0.25 38.4±2.12 35.1±2.33 0.501a 
A2 3.2±0.28 39.1±1.96 35.9±2.15 0.512a 
A3 3.6±0.46 40.3±2.41 36.7±2.46 0.524a 
C 3.4±0.57 35.7±2.25 32.3 ±2.96 0.461b 
Note The data with the different superscript letter are significantly different (P<0.05), and vice versa 
(P>0.05). The fo llowings are the same as here.  
3.6. Macroscopic lung lesions and PCR detection of M hyo DNA in BALF 
The result of the percentage of macroscopic lung lesions was concluded inTable 2. The mean percent lung 
involvement was significantly lower in  treated pigs than in control p igs after challenge test (P <0.05), and there 
is no marked difference among three treated groups (P>0.05). The score of lung lesions by severity is also 
summarized in  Table 2. The macroscopic lung lesion scores for the control pigs averaged  23.13 3.54 in 
challenge study, and 6.21±0.52, 5.31±0.43 and 4.52±1.26  respectively for A1, A2 and A3 t reated group pigs. 
The result suggest that the severity of lung lesions of control pigs is significantly h igher than those of the 
treated pigs (P<0.05), which manifested less lesions and the differences are not remarkable among them 
(P>0.05).  
Table 2 Mycoplasma hyopneumoniae (M hyo)lung lesions scoring and PCR detection of M hyo DNA from the 
nose swab and BALF of the experimental pigs after challenge 
Group No. of pigs 
Lung  involvement (%) 
Lesion Scores No of PCR detection 
positive (%) 
mean±SE Range mean±SE Range Swabs 14-70 DPV 
BALF 
28 DPC 
A1 10 6.3±1.3b 2-20 6.21±1.52b 2-12 0/10(0%) 3/10(30%) 
A2 10 5.1±0.8b 1-17 5.31±1.43b 1-10 0/10(0%) 2/10(20%) 
A3 10 3.7±0.9b 0-14 4.52±1.26b 0-9 0/10(0%) 2/10(20%) 
C 10 23.5±1.6a 4-53 23.13±3.54a 7-46 0/10(0%) 6/10(60%) 
Note: DPV: days post vaccination; DPC: days post challenge. 
The results for PCR detection of M hyo pathogen in BALF samples were listed in the table 2, which  showed 
after the challenge, 6 samples of the control group was found to be positive for M hyo pathogen(6/10), and the 
challenged A1, A2 and A3 group respectively manifested 30%(3/10), 20%(2/10) and 20%(2/10) positive for M 
hyo pathogen. In contrast, all the pigs appeared to be negative for M hyo DNA before the challenge. Th is 
indicated that treated groups were better protected to different extents by the inoculation with the recombina nt 
plasmids entrapped with chitosan naoparticles compared to the control.  
4. Discussion 
At present, one of the most important measures to control EP is vaccination of pigs. The currently used M 
hyo vaccines can reduce the number of organis ms in the respiratory tract and may decrease the infection level 
in a herd [14, 20]. The main effects of vaccination include reduced clinical symptoms (lung lesions), 
medication use and reduced loss of growth performance of the pigs have been extensively proven  [20], but the 
protection of currently available vaccines seems to be incomplete since vaccinated pigs can be re-infected [12, 
10]. The enhancement of both humoral and cellular immunity after vaccination is probably of importance in the 
protection against swine respiratory diseases [18]. Unfortunately, the immune mechanis ms responsible for 
protection against M hyo are complex and not clearly understood. There is no positive correlation between the 
vaccine-provoked serum antibody levels and protection against M hyo [22, 18]. Acquired maternal antibody 
can delay the appearance of antibody responses to M hyo in piglets from vaccinated dams [21, 23] but sow 
vaccination increased the percentage of seropositive sows and piglets at  weaning and reduced significantly the 
mean EP-compatib le lung lesion score at slaughter [24]. 
A few studies have reported the proliferative responses of lymphocytes  of pigs to M hyo-specific antigens [22, 
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18]. The intramuscular in jection of vaccine could induce the generation of IFN - secreting cells in the blood of 
pigs [18], and the infect ion of macrophages with M hyo increased the release of TNF- , IL-1 , IL-6 that maybe 
correlated with the lesions of infection [25]. The level of humoral immunity in M hyo vaccinated pigs was not 
positively correlated with the p rotective immunity, and the proliferative responses of lymphocytes to M hyo also 
showed inverse variation [22, 18], therefore the relationship between detailed cellular immunity and protection 
against M hyo is still unclear.  
In this study, our research focused main ly on whether the fusion porcine IL-4/6 gene (PIL4/6) encapsulated 
in CNP could elevate immunity of piglets to Mycoplasma vaccine and the protection against challenge. Herein 
our results firstly revealed that the inoculation with VRPIL4/6-CNP could successfully promote the immunity 
in vivo of the vaccinated piglets. It was found that the concentration of specific antibody, immunoglobulin, IL-2, 
IL-4 and IL-6 as well as IFN-  in the treated piglets were significantly h igher than those of the control piglets 
(P<0.05); the CD3+ T cells, CD4+ TH and CD8+ TC also significantly increased in the blood of the treated 
groups in comparison with  those of the controls  group inoculated with  VR1020-CNP;  so did the numbers of  
the lymphocytes and monocytes in the treated piglets  (P<0.05). These results clearly implied that the expression 
of VRPIL4/6 could enhance the humoral and cellular immunity of p iglets to M hyo vaccine.   
Similarly, the increase of IFN- the blood and the more pronounced proliferative responses 
of lymphocytes following in vitro stimulation with M hyo-specific antigen were also observed in pigs following 
M hyo vaccination [18]. These improvements of the immunity against Mycoplasma pneumonia suggested that 
VRPIL4/6-CNP is a powerful and promising immune ad juvant to promote the humoral and  cellular immunity 
in piglets to M hyo vaccine which could in turn elevate protection of piglets against M hyo.  
Obviously, the challenge test demonstrated that the inoculation with VRPIL4/6-CNP significantly potentiate 
the protection of treated pigs  against M hyo infection in comparison with the control in respect to lung lesion 
severity, involvement of challenged pigs and detection rate of M hyo (P<0.05). The relationship between dose 
and the effect of the fusion PIL-4/6 gene is important for the practical cost-effective utilization of adjuvant to 
control M hyo infection of pigs. Therefore, the different doses of VRPIL4/6-CNP inoculation  were designed in 
our experiment to evaluate the dose-effect on the immune responses of piglets to M hyo vaccine. The increased 
dose of VRPIL4/6-CNP really resulted in the obvious enhancement of immunity in A2 group (1 mg/per pig). 
However, further increase of VRPIL4/6-CNP (to 1.5 mg/pig) did not lead to any more evident elevation of 
immune responses in the A3 piglets compared with A2 (P>0.05). Of course, the optimal dose of VRPIL4/6-
CNP for M hyo vaccination of pig need further field experiments to clarify.  
Interestingly, during the 70-day observation period, all the treated pig lets in the three groups actually did not 
manifest any local inju ries or systemic symptoms, such as  edema and inflammat ion at the injected spot, fever or 
loss of weight gain. Conversely, the persistent enhancement of the immunity was in consistent with the better 
growth performance of the treated piglets, which is meaningful for the practical applicat ion of VRPIL4/6-CNP 
adjuvant compared to the short bioactivity in vivo of traditional adjuvants.  
In conclusion, the results in our experiments demonstrated that the fusion PIL-4/6 gene entrapped with 
chitosan nanoparticle could significantly promote the humoral and cellular immunity of pig to M hyo vaccine, 
and improve the protection efficacy of vaccination against challenge with virulent M hyo strain. These suggest 
that it could be a novel p romising adjuvant for enhancing the protective immunity of pig against M. 
hyopneumoniae.  
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